Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positive elements like growth in medical essentials and connected care, strong cash flow, and confidence in future revenue and margin performance, there are concerns. The decline in biopharma systems, adjusted gross margin decrease, and lack of clarity on certain future projections temper optimism. The strategic focus on share repurchases and productivity improvements is positive, but headwinds from Alaris and China, and the temporary ship hold on ChloraPrep, introduce uncertainties. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Key Financial Performance
Revenue $4.7 billion, up 2.6% year-over-year. Growth driven by double-digit growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration. Partially offset by focused pressure in Alaris, vaccines, and China.
Adjusted Operating Margin 24.2%, down 110 basis points year-over-year. Includes 160 basis points of tariffs and increased commercial investments in key growth areas. However, margins were ahead of expectations.
Adjusted EPS $2.90, up 3.9% year-over-year. Reflects solid revenue performance, better-than-expected margins, and strong operational execution.
Medical Essentials Growth 1.7% year-over-year. Growth in the U.S. driven by share gains in Vascular Access Management and BD Vacutainer portfolio. Partially offset by market dynamics in China.
Connected Care Growth 3.3% year-over-year. Advanced Patient Monitoring grew 12% on strength in U.S. consumables. MMS grew modestly due to a difficult prior year comparison in Alaris capital, offset by strong infusion sets performance.
BioPharma Systems Declined 1.8% year-over-year. Double-digit growth in Biologics led by GLP-1s was offset by lower demand for vaccine products.
Interventional Growth 5.3% year-over-year. Growth led by PureWick, double-digit growth in Infection Prevention and Advanced Tissue Regeneration, and strength in peripheral vascular disease and oncology. Partially offset by China market dynamics.
Adjusted Gross Margin 54.7%, down 90 basis points year-over-year. Includes 70 basis points of positive benefit from productivity and mix, offset by 160 basis points of tariffs.
Free Cash Flow $1.1 billion year-to-date, up significantly versus the prior year. Driven by disciplined working capital management, improved collections, and inventory management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Biologic Drug Delivery: Achieved double-digit growth, becoming a key growth platform.
Advanced Patient Monitoring (APM): Grew above market with strong HemoSphere Alta adoption and a 20% increase in Smart Recovery consumables demand.
PureWick Portfolio: Continued adoption, including expansion of PureWick at-home initiative and adoption in the VA.
Advanced Tissue Regeneration: Delivered mid- to high single-digit growth.
Peripheral Intervention: Launched EnCor EnCompass Biopsy System in the U.S. and Revello Vascular Covered Stent in Europe, expanding into new procedural segments.
HemoSphere Stream Module: Expanded launch in the U.S. and Europe, enabling continuous noninvasive blood pressure monitoring.
Connected Care: Achieved measurable share gains and customer conversions, with APM growing 12%.
BioPharma Systems: Secured significant long-term customer wins, including next-generation GLP-1 programs with leading pharmaceutical companies.
Interventional: Built competitive momentum globally in Surgery and UCC, with strength in synthetic hernia and Advanced Tissue Regeneration portfolio.
Operational Excellence: Achieved 8% productivity improvement and service levels over 90% through BD Excellence system.
Manufacturing Network: Reduced footprint to around 50 sites globally, with further reductions underway.
Cost-Out Program: Progressed on $200 million cost-out program, achieving a $150 million run rate.
Adjusted Operating Margin: Delivered 24.2% adjusted operating margin, reflecting strong operational execution.
Capital Allocation: Returned $2.3 billion to shareholders, including $2 billion in share repurchases, and retired $2.1 billion of debt.
FDA Warning Letter: Addressed FDA warning letter for El Paso facility by voluntarily placing products on ship hold for additional testing.
New BD Strategy: Focused on competing, innovating, and delivering, with improved visibility into long-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Alaris, vaccines, and China market dynamics: The company faced expected pressure in these areas, which impacted revenue performance. These factors represent less than 10% of revenue but are being managed with discipline.
FDA warning letter for El Paso facility: The FDA issued a warning letter related to the El Paso, Texas facility that manufactures ChloraPrep and PurPrep infection prevention products. The company voluntarily placed these products on ship hold in the U.S. while additional final release testing is conducted. This could potentially disrupt supply and impact revenue.
Tariffs: Tariffs negatively impacted adjusted gross margin by 160 basis points and adjusted operating margin by 160 basis points, creating financial pressure.
China market dynamics: Market dynamics in China negatively affected performance in certain segments, including Medical Essentials and Peripheral Intervention.
Noncash asset impairment charges: The company recorded approximately $450 million in noncash asset impairment charges following the separation of its Life Sciences business and the exit of certain activities that no longer align with its strategy. This reflects challenges in aligning resources and simplifying operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year Adjusted EPS Guidance: BD is raising its full year adjusted EPS guidance to $12.52 to $12.72, reflecting confidence in the New BD strategy and improved visibility into the remainder of the year.
Revenue Growth: BD reaffirms its full-year revenue guidance of low single digits, with second-half revenue growth expected to be roughly similar to the first half. Currency is estimated to be a tailwind of about 120 basis points.
Adjusted Operating Margins: BD expects adjusted operating margins of approximately 25%, inclusive of the impact of tariffs.
Capital Allocation: BD remains committed to its capital allocation framework, prioritizing shareholder returns, disciplined tuck-in M&A, and maintaining a strong balance sheet. The company targets a long-term net leverage of 2.5x.
Product Launches and Pipeline: BD plans to launch the Revello Vascular Covered Stent in the U.S. next fiscal year, expanding its peripheral vascular portfolio. The company is also accelerating its R&D pipeline, reducing time to launch by over 10 months on average for key programs.
Operational Efficiency: BD is reducing its manufacturing footprint to around 50 sites globally, with further reductions planned. The company has achieved approximately 8% productivity in the quarter and is on track to complete a $200 million cost-out program by the end of next year.
Market Trends and Growth Platforms: BD is focusing on scaling growth platforms in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration, which are expected to drive long-term growth. Biologics are projected to represent about 55% of the BioPharma Systems segment revenue.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: During the quarter, BD returned approximately $0.3 billion to shareholders in the form of dividends.
Share Repurchases: BD returned $2 billion to shareholders through share repurchases during the quarter.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the headline organic growth for the quarter and what segments were impacted by one-time headwinds?
A:Headline organic growth was 2.6%. The one-time headwinds impacted various segments, but the overall portfolio grew solid mid-single digits, around 5%. TSA income was not a driver of the performance.
Q:How does management view revenue and margin performance for the back half of the year?
A:Management feels confident about revenue and margin performance for the back half of the year. They expect similar growth rates as the first half, driven by BD Excellence initiatives and productivity improvements. They also anticipate reduced headwinds from vaccines in the latter part of the year.
Q:What is the capital allocation strategy for BD, and how does it prioritize share repurchase and M&A?
A:BD prioritizes share repurchase due to the undervaluation of its stock, followed by a strong dividend and focused tuck-in M&A. The company remains disciplined in M&A, targeting deals that accelerate revenue growth, drive margins, and improve return on invested capital.
Q:What is the status of the ChloraPrep ship hold and its impact on guidance?
A:ChloraPrep products are on a temporary ship hold due to additional testing requirements. Management expects the hold to last approximately 3 weeks, pending satisfactory test results. The company continues manufacturing during this period, and there is no anticipated long-term impact on guidance.
Q:What are Vitor Roque's priorities as the new CFO?
A:Vitor Roque's priorities include driving growth, maintaining clear and consistent communication, delivering on commitments, and staying disciplined with capital allocation. He aims to sharpen execution without changing the company's strategic direction.
Q:What are the growth opportunities within the MMS segment, including Alaris and pharmacy automation?
A:Alaris is gaining market share with a competitive funnel at its largest in company history. Infusion sets grew low double digits, driven by share gains. Pyxis Pro, the next-generation AI-enabled platform, is seeing strong competitive traction. Pharmacy automation, including Parata and Rowa, is positioned to address labor shortages and support direct-to-consumer pharmaceutical services.
Q:How is BD Excellence contributing to operational and financial performance?
A:BD Excellence has driven record safety, quality, and delivery levels, achieving 8% productivity. It has also improved commercial and R&D processes, pulling project timelines forward by an average of 10 months. The initiative is seen as a long-term strategic advantage.
Q:What is BD's outlook on GLP-1 treatments and their impact on the pharmaceutical business?
A:BD views oral GLP-1 treatments as complementary to injectables, which remain the backbone of the category. The company has signed over 80 biosimilar deals and continues to see GLP-1s as a strong growth driver. Biologics now account for about 55% of the pharma systems business unit revenue.
Q:What are the expected headwinds from Alaris, vaccines, and China, and how will they evolve?
A:Alaris will contribute a 200 basis point headwind in FY27 but will stabilize afterward. Vaccine-related headwinds are not expected to repeat at the same scale next year. China's contribution to revenue is decreasing and is expected to drop below 4% of BD's portfolio.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the weighted average market growth rate (WAMGR) of the portfolio and how it will evolve over the next 24-36 months. They also did not provide clarity on the exact timeline for Alaris headwinds to subside within FY27.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advanced Tissue
Alaris share
Alaris vaccine
BD Excellence
BD finance
CFO
China
Connected Care
Europe
Life
New BD
President Investor
PureWick
Tissue Regeneration
Vitor
breadth
candidate
capital allocation
confidence
date
discipline
disease
finance function
framework capital
launch
leverage capital
point basis
portfolio contribution
pressure Alaris
priority
release
resilience
share gain
shareholder value
testing
visibility remainder
BDX Transcript
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents a mixed picture. While there are positive elements like growth in medical essentials and connected care, strong cash flow, and confidence in future revenue and margin performance, there are concerns. The decline in biopharma systems, adjusted gross margin decrease, and lack of clarity on certain future projections temper optimism. The strategic focus on share repurchases and productivity improvements is positive, but headwinds from Alaris and China, and the temporary ship hold on ChloraPrep, introduce uncertainties. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Casey's General Stores, Inc. (CASY) Q3 2026 Earnings Call Transcript
Positive3-10
The strategic plan outlines positive initiatives such as share buybacks, innovation investments, and cost optimization, which are likely to bolster market sentiment. Despite challenges like tariff headwinds and revenue declines in specific segments, the company maintains stable margins and optimistic EPS growth. The Q&A insights reveal effective management of external factors and growth strategies, further supporting a positive outlook. These elements collectively suggest a positive stock price movement over the next two weeks.
Becton, Dickinson and Company (BDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
BDX Slides
BDX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
